Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(3):e32534.
doi: 10.1371/journal.pone.0032534. Epub 2012 Mar 6.

HIV-1 disease progression is associated with bile-salt stimulated lipase (BSSL) gene polymorphism

Affiliations

HIV-1 disease progression is associated with bile-salt stimulated lipase (BSSL) gene polymorphism

Martijn J Stax et al. PLoS One. 2012.

Abstract

Background: DC-SIGN expressed by dendritic cells captures HIV-1 resulting in trans-infection of CD4(+) T-lymphocytes. However, BSSL (bile-salt stimulated lipase) binding to DC-SIGN interferes with HIV-1 capture. DC-SIGN binding properties of BSSL associate with the polymorphic repeated motif of BSSL exon 11. Furthermore, BSSL binds to HIV-1 co-receptor CXCR4. We hypothesized that BSSL modulates HIV-1 disease progression and emergence of CXCR4 using HIV-1 (X4) variants.

Results: The relation between BSSL genotype and HIV-1 disease progression and emergence of X4 variants was studied using Kaplan Meier and multivariate Cox proportional hazard analysis in a cohort of HIV-1 infected men having sex with men (n = 334, with n = 130 seroconverters). We analyzed the association of BSSL genotype with set-point viral load and CD4 cell count, both pre-infection and post-infection at viral set-point. The number of repeats in BSSL exon 11 were highly variable ranging from 10 to 18 in seropositive individuals and from 5-17 in HRSN with 16 repeats being dominant (>80% carry at least one allele with 16 repeats). We defined 16 to 18 repeats as high (H) and less than 16 repeats as low (L) repeat numbers. Homozygosity for the high (H) repeat number BSSL genotype (HH) correlated with high CD4 cell numbers prior to infection (p = 0.007). In HIV-1 patients, delayed disease progression was linked to the HH BSSL genotype (RH = 0.462 CI = 0.282-0.757, p = 0.002) as was delayed emergence of X4 variants (RH = 0.525, 95% CI = 0.290-0.953, p = 0.034). The LH BSSL genotype, previously found to be associated with enhanced DC-SIGN binding of human milk, was identified to correlate with accelerated disease progression in our cohort of HIV-1 infected MSM (RH = 0.517, 95% CI = 0.328-0.818, p = 0.005).

Conclusion: We identify BSSL as a marker for HIV-1 disease progression and emergence of X4 variants. Additionally, we identified a relation between BSSL genotype and CD4 cell counts prior to infection.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. BSSL genotype distribution.
(A) BSSL genotype distribution in high risk seronegative (HRSN, n = 48) individuals and HIV-1 positive individuals (n = 334). (B) Within the group of HIV-1 positives, individuals with fast disease progression (progression to AIDS or CD4 cell count <200 cells/µl within 3 years after seroconversion, n = 21) were compared to individuals with slow disease progression (time to AIDS or CD4 cell count <200 cells/µl is 10 years or longer after seroconversion, n = 63). We pre-defined 16–18 repeats as high (H) and less than 16 repeats as low (L) repeat numbers. BSSL genotype frequencies were compared for individuals with two low (LL), one low and one high (LH) or two high repeat numbers (HH). BSSL genotype distributions were different between individuals with slow disease progression when compared to individuals with fast disease progression (Pearson Chi-square p = 0.026). Additionally, HRSN were compared to the whole study population of seropositive individuals (all) for the LL, LH and HH genotypes (p = 0.190).
Figure 2
Figure 2. AIDS-free and CXCR4-free survival from HIV-1 seroconversion with and without BSSL HH genotype.
Kaplan Meier estimation of patients with HH and non-HH (LL+LH) genotypes using (A+B) AIDS-free survival plotted for (A) all genotypes (LL n = 47, LH n = 139, HH n = 139, log rank p = 0.063), (B) HH versus LL+LH genotypes (HH n = 139, non-HH n = 186) (log rank p = 0.033) or (C+D) first detection of CXCR4-using HIV-1 variants as an endpoint for (C) all genotypes (LL n = 41, LH n = 126, HH n = 127, log rank p = 0.106) or (D) HH versus LL+LH genotypes (HH n = 127, non-HH n = 167, log rank p = 0.085).
Figure 3
Figure 3. AIDS-free survival from HIV-1 seroconversion with and without the BSSL LH genotype.
Kaplan Meier estimation of patients with LH and non-LH (LL+HH) genotypes using AIDS-free survival plotted LH versus LL+HH genotypes (log rank p = 0.025).
Figure 4
Figure 4. BSSL HH genotype is associated with high CD4 cell numbers pre-seroconversion.
The relation between BSSL genotypes and CD4 cell count before seroconversion for individuals with the (A) LL, LH and HH genotypes (p = 0.022) and (B) HH versus non-HH (LL+LH) genotypes (p = 0.007). Median values are indicated with a horizontal line. NS: not significant, *: p<0.05, **, p<0.01.

Similar articles

Cited by

References

    1. Paxton WA, Kang S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin Immunol. 1998;10:187–194. - PubMed
    1. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277:959–965. - PubMed
    1. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389–393. - PubMed
    1. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A. 1999;96:4581–4585. - PMC - PubMed
    1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657–700. - PubMed

Publication types